Roberto Gedaly

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Roberto Gedaly sits in the upper half of US sponsors by registered trial count (#4,885 of 15,742 sponsors by registered trial count).

2 total trials 1 currently recruiting 1 completed early-phase tilt upper half by trial count

Roberto Gedaly: 2 sponsored US clinical trials, 1 recruiting.

Roberto Gedaly sponsors 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 1 completed. 0 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is End Stage Renal Disease, with 2 trials.

Mid-pack sponsor footprint

Roberto Gedaly is in the upper half of sponsors by trial count (#4,885 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.

What is open in the Roberto Gedaly pipeline

1 recruiting of 2 indexed (50% open); 1 completed (50%).

Phase mix: 0 late (III/IV) vs 2 early (I/II) (early-phase heavy).

Top condition: End Stage Renal Disease (2 trials), 1 other listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Roberto Gedaly: open-pipeline peers nationwide

Peers matched on 2 registered trials and 50% open enrollment, not the therapeutic-area sidebar.

Roberto Gedaly sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 1.522.533.544.5 0%20%40%60% Total trials Recruiting share Roberto Gedaly1200 Pharma1ST Biotherapeutics3 Waves Wellness3EO Health3ive Labs60 Degrees Pharmaceuticals7 Hills PharmaAbcentra
Roberto Gedaly sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Roberto Gedaly sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 2 trials (± recruiting share)

Sponsors near 50% open enrollment (± trial volume)

What to do with this Roberto Gedaly page

2 registered trials is a research-attention snapshot, not an endorsement of Roberto Gedaly or any single study.

  • 1 of Roberto Gedaly's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • End Stage Renal Disease is the condition Roberto Gedaly studies most, compare against other sponsors active in the same condition before evaluating a specific study. See End Stage Renal Disease trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Roberto Gedaly pipeline card: 2 registered trials from official public datasets.Report a data error.